The company has scheduled an Analyst/Institutional Investor meeting with Millennium Management to be conducted virtually on 19th June, 2026.
The meeting is being intimated under the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure explicitly states that the schedule of the meeting is subject to change due to exigencies on the part of either the Investor or the Company.
Management participation: The disclosure is signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer of Alkem Laboratories Limited.
The document does not indicate whether any presentation, earnings deck, transcript, or recording will be made available.
The company has not indicated whether unpublished price sensitive information (UPSI) will be shared during the meeting.
No financial highlights, guidance references, or presentation summaries are included in this disclosure.
Additional Notes Section
The document is a formal intimation letter addressed to both BSE Limited and the National Stock Exchange of India Limited.
No attachments were mentioned or included with this disclosure.
No financial data or performance figures were disclosed in this announcement.
